title: Epstein-Barr virus-carrying B cells in the blood during acute infectious mononucleosis give rise to lymphoblastoid lines in vitro by release of transforming virus and by proliferation.
abstract: In accordance with earlier studies, we detected higher numbers of Epstein-Barr virus (EBV)-carrying lymphocytes (B-EBV) in the blood of acute infectious mononucleosis (IM) patients and higher amounts of transforming EBV particles in the saliva compared to healthy seropositive individuals. B cells grew in cultures seeded with the low and high density IM lymphocytes. The majority of B cells which grew acquired the infection in vitro (2-step outgrowth), because addition of virus neutralizing antibodies considerably reduced the emergence of lymphoblastoid cell lines (LCLs). Only the minority of the explanted B-EBV cells proliferated. The antiviral drug phosphonoformate (PFA) did not influence the frequency of 2-step LCLs in the IM cultures. This may indicate that a large proportion of EBV carrying B cells have already entered the viral productive cycle in vivo and passed the PFA-sensitive stage at the time of explantation. Earlier experiments with blood of healthy seropositive individuals showed an inhibitory effect of PFA on the generation of LCLs. One healthy individual who entered this study as a control, probably had a reactivated EBV infection as judged by the anti-EA activity in his serum and the high level of virus in his saliva. He had antibodies against EBV nuclear antigens (EBNA), and therefore he did not have a primary infection at the time of the test. Judged by the number of wells with B cell growth, the frequency of virus-carrying B cells in his blood was low. It seems that anti-EBV immunity can control the number of infected B cells in the blood, but does not influence the virus load in the epithelial cells.
authors.affiliation: Department of Tumor Biology, Karolinska Institute, Stockholm, Sweden.
authors.forename: N
authors.initials: N
authors.lastname: Lewin
authors.forename: P
authors.initials: P
authors.lastname: Aman
authors.forename: B
authors.initials: B
authors.lastname: Akerlund
authors.forename: E
authors.initials: E
authors.lastname: Gustavsson
authors.forename: C
authors.initials: C
authors.lastname: Carenfelt
authors.forename: L
authors.initials: L
authors.lastname: Lejdeborn
authors.forename: G
authors.initials: G
authors.lastname: Klein
authors.forename: E
authors.initials: E
authors.lastname: Klein
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000914:Antibodies, Viral / Q000097:blood; D000956:Antigens, Viral / Q000276:immunology; D001402:B-Lymphocytes / Q000276:immunology* / Q000382:microbiology; D036022:Capsid Proteins; D002472:Cell Transformation, Viral; D002478:Cells, Cultured; D019309:Epstein-Barr Virus Nuclear Antigens; D017245:Foscarnet; D004854:Herpesvirus 4, Human / Q000187:drug effects / Q000276:immunology / Q000502:physiology*; D006801:Humans; D007244:Infectious Mononucleosis / Q000276:immunology* / Q000382:microbiology; D008213:Lymphocyte Activation / Q000276:immunology*; D010746:Phosphonoacetic Acid / Q000031:analogs & derivatives / Q000494:pharmacology; D012463:Saliva / Q000382:microbiology
chemical_list: D000914:Antibodies, Viral; D000956:Antigens, Viral; D036022:Capsid Proteins; D019309:Epstein-Barr Virus Nuclear Antigens; C041788:Epstein-Barr viral capsid antigen; C033305:Epstein-Barr virus early antigen; D017245:Foscarnet; D010746:Phosphonoacetic Acid